Tumor antigen

Details Tumor antigen Tumor antigen

2002-02-01

2008-12-16

Ewoldt, G. R. (Department: 1644)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Amino acid sequence disclosed in whole or in part; or...

C514S015800, C530S328000

Reexamination Certificate

active

07465452

ABSTRACT:
The present invention relates to a tumor antigen peptide capable of inducing and/or activating HLA-A24-restricted and/or HLA-A2-restricted and tumor-specific cytotoxic T lymphocytes. The present invention also relates to a method of providing a polynucleotide encoding the peptide and a complementary strand thereto, a recombinant vector containing the polynucleotide, a transformant containing the recombinant vectors. The present invention also relates to a method for producing the peptide, an antibody against the peptide, a compound interacting with these entities and a method for screening for the compound, a pharmaceutical composition utilizing these entities, and a means for the diagnosis utilizing these entities.

REFERENCES:
patent: 5432076 (1995-07-01), Rudd et al.
patent: 5734023 (1998-03-01), Nag et al.
patent: 6635623 (2003-10-01), Hoogeveen et al.
patent: 2004/0141992 (2004-07-01), Itoh et al.
patent: 2005/0019341 (2005-01-01), Itoh et al.
patent: WO 97/22255 (1997-06-01), None
patent: WO 98/46996 (1998-10-01), None
Marchand et al (Int. J. Cancer 20: 219-230, 1999).
Marchand et al (Exp. Opin. Biol. Ther. 1(3): 497-510, 2001).
Bodey et al (Anticancer Research 20: 2665-2676, 2000).
Gao et al (J. Immunother. 23: 643-653, 2000).
Merck Manual 16thEdition, 1992, Merck Research Laboratories, Rahway, N.J., p. 21.
Encyclopedia Brittanica Online. 2004, 2 pages, search.eb.com/eb/print?eu=76559.
Paul (Fundamental Immunology, 2nd Edition, Raven Press, NY, 1989, p. 1006).
Bergmann et al. J. Virol. 1994 68(8): 5306-5310.
Wang et al. Cell. Immunol. 1992 143; 284-297.
Perkins et al. J. Immunol. 1991 146(7): 2137-2144.
Theobald et al. J. Exp. Med. 1998, 188(6): 1017-1028.
Gileadi et al. Eur. J. Immuno. 1999, 29: 2213-2222.
Eisenlohr et al. J. Exp. Med. 1992, 175: 481-487.
Shastri et al. J. Immunol. 1995, 155: 4339-4346.
Engelhard, V.H., Curr. Opin. Immunol. 1994, 6: 13-23.
Guo et al. Nature, 1992, 360: 364-366.
Wiley InterScience Journal Abstract of European J. Immunol. vol. 31, Issue 2, pp. 323-332, published online: Jan. 22, 2001.
De Bruijin et al. Eur. J. Immunol. 1991, 21: 2963-2790.
Boon et al (Ann. Rev. Immunol. 2006, 24: 175-208).
Voronova, A. F. et al.: “Expression Of A New Tyrosine Protein Kinase In Stimulated By Retrovirus Promoter Insertion” Nature (London), vol. 319, No. 6055, 1986, pp. 682-685.
Rosenberg, S. A. et al.: “Immunologic And Therapeutic Evaluation Of A Synthetic Peptide Vaccine For The Treatment Of Patients With Metastatic Melanoma”, Nature Medicine, Nature Publishing, Co, US, vol. 4, No. 3, Mar. 1, 1998, pp. 321-327.
Lindauer, Markus et al.: “The Molecular Basis Of Cancer Immunotherapy By Cytotoxic T Lymphocytes”, Journal of Molecular Medicine (Berlin), vol. 76, No. 1, Jan. 1998, pp. 32-47.
European Search Report for EP 00 94 9982, Oct. 11, 2002.
Megumi Kikuchi, et al., “Identification of a Sart-1-Derived Peptide Capable of Inducing HLA-A24-Restricted and Tumor-Specific Cytotoxic T Lymphocytes”, Int. J. Cancer, 1999, vol. 81, pp. 459-466.
Yasuhiro Koga, et al., “A Human T Cell-Specific cDNA Clone(YT16)Encodes A Protein With Extensive Homology To A Family of Protein-Tyrosine Kinases”, Eur. J. Immunol. 1986, vol. 16, pp. 1643-1646.
Akio Tanaka, et al., “DNA Sequence Encoding The Amino-Terminal Region of the Human c-src Protein: Implications of Sequence Divergence Among src-Type Kinase Oncogenes”, Molecular and Cellular Biology, May 1987, pp. 1978-1983.
Nanae Harashima, et al., “Recognition of the Lck Tyrosine Kinase as a Tumor Antigen by Cytotoxic T Lymphocytes of Cancer Patients with Distant Metastases”, Eur. J. Immunol., 2001, vol. 31, pp. 323-332.
Nobue Imai, et al., “Identification of Lck-Derived Peptides Capable of Inducing HLA-A2-Restricted and Tumor-Specific CTLS in Cancer Patients with Distant Metastases”, Int. J. Cancer, 2001; vol. 94, pp. 237-242.

Affiliated with

Also associated with

Rating

Tumor antigen does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tumor antigen, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor antigen will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4041155